Pharmaceutical R&D Innovation and Outsourcing Management Conference

　　Your Reasons to Attend

 

　　There is a generally acknowledged fact in the pharmaceutical industry that the research and development of a new drug have three features: high-investment, a long-cycle and high-risk. Usually, the R&D cycle of the new drug development is around 8 to 14 years, and the cost is from $800 million to $1000 million. Due to the validity of the patent terms, people hope to shorten the R&D cycle in order to ensure the products enter the market earlier and get more profits as soon as possible. Thus, shortening the period of the research and development, controlling costs and reducing the risks of failure of R&D have become key issues. Along with the increasingly fierce competition in the global drug market, there appears an obvious labour division in the whole industry chain, and more and more international giants have shown a general trend towards concentrating on core business and outsourcing non-core business. From screening research, R&D, clinical trials, audits and OEMs of drug compounds through to the marketing value chain, these are all gradually becoming supporting services provided by professional service companies, which, through the ideals of sharing benefit-risk, eventually form a complete value chain. Further, pharmaceutical enterprises are eager to learn how to be in charge of the high-quality R&D for new drugs and grasp every strategic decision successfully.

 

　　The 2014 Pharmaceutical R&D Innovation and Outsourcing Management Conference, which will run concurrently with CPhl China, will focus on promoting the formation of a CRO and CMO alliance and deepening the exchange and cooperation among CROs, CMOs and pharmaceutical companies.

 

　　Highlights

 

　　Develop R&D innovation and promote productivity in the field of drug discovery

 

　　Foster the commoditisation of R&D results within China's market for sustainable development and innovation

 

　　Get in touch with the latest development trends in the global pharmaceutical contract services industry

 

　　Learn how to take advantage in China in terms of costs, human resources, infrastructure and other areas

 

　　Study the successes of CRO and CMO magnates and build on the collaborations among CROs, CMOs and pharmaceutical companies

　　Module II: R&D Innovation and Management in Pharmaceutical Enterprise

 

　　13:00  Topic 3: Assessments cover science and risk

 

　　Monitoring the benefit-risk balance is critical at each stage across the life-cycle of drug development, review and post-approval activities. A Benefit-Risk assessment framework is recognised as important from both an agency and a company perspective. It is a rapidly moving field involving a number of ongoing initiatives across regulatory agencies and companies. The presentation will:

 

　　" Present the progress made on defining and implementing a benefit-risk methodology framework

 

　　13:40 Topic 4: Effective implementation and application  of the outsourcing  supplier management model

 

　　In recent years, the business of outsourcing companies has expanded to cover almost the entire drug development process. A growing number of pharmaceutical companies are starting to think about how outsourcing supplier management models work:

 

　　" The negotiation process and strategy

 

　　" Cooperative bargaining and project management

 

　　" Multi-level communication strategies

 

　　Man Zhiwei, GM, Otsuka Beijing Research Institute

 

　　14:20 Topic 5: Establish long-term partnership strategies with CMO companies and maintain effective communication

 

　　" Supplier selection

 

　　" Sharing successful cooperation projects and their interpretation

 

　　" The benefits of effective CMO selection and management

 

　　Sherry Gu, Head of Strategic Partnership, SBS Asia , Boehringer Ingelheim GmbH

 

　　15:00  Networking and Coffee Break

 

　　15:20  Topic 6: The green chemistry process for API production and CRO, CMO manufacturing

 

　　Along with the development of the pharmaceutical industry, the questions of solving environmental contamination and creating a sustainable development have received more and more attention. Due to many pharmaceutical and CRO, CMO companies' lack of attention to environmental awareness, the social responsibility of the pharmaceutical industry has been questioned. How to create green technological environments in the R&D process has become a focus for the pharmaceutical industry. In this session, the speaker will share some ideas and cases on how Roche deals with this problem of environmental protection.

 

　　Du Zhengming , Head of Process Research and Synthesis , Roche China R&D Center

 

　　16:00 Topic 7: A procurement view of supplier relationship management

 

　　Working with suppliers is no longer a simple task of selecting the best quality for the best price. Supplier Relationship Management enables further value contribution from procurement towards our business objective. It is one of the key drives for Procurement's value creation and fits seamlessly into strategic sourcing process after a supplier is selected or a new contract is negotiated. Clear roles and responsibilities ensure efficient and effective supplier management process. Within supplier relationship management the main drive is for a focused approach through segmentation of supply base and management processes which include Risk management, Performance management, Contract management and Supplier development.

 

　　Global Strategic Sourcing Manager, Asia, Bayer HealthCare